Clinical Trials

GSK begins patient dosing in phase 3 trial of RSV maternal candidate vaccine

British drugmaker GlaxoSmithKline (GSK) has started patient dosing in a phase 3 clinical trial to assess the safety and efficacy of the respiratory syncytial viirus (RSV) vaccine candidate for maternal immunisation.

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

Pfizer announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.

AstraZeneca’s AZD1222 vaccine demonstrates promising efficacy

AstraZeneca announced that its AZD1222 vaccine has demonstrated a significant effect in preventing Covid-19 in an interim analysis of clinical trials in the UK and Brazil.

Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the treatment of Covid-19.

Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

Pfizer and BioNTech have announced that their BNT162b2 Covid-19 vaccine candidate has achieved all primary efficacy endpoints in the phase 3 study.

Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.

Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1

Merck announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP) option in women and adolescent girls at high risk for acquiring HIV-1 infection in sub-Saharan Africa.

Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study

Moderna announced that its mRNA-1273 Covid-19 vaccine candidate has shown a significant effect against Covid-19 patients in phase 3 COVE study.

Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

Inovio has secured approval from the US Food & Drug Administration (FDA) to begin phase 2 segment of its planned phase 2/3 clinical trial for its Covid-19 DNA vaccine candidate.